“As part of the University of Oxford's global randomized clinical trials of the coronavirus vaccine, our normal assessment process was triggered and we voluntarily paused vaccinations to allow for an assessment of the safety data by an independent committee ”.
It is with this press release that the pharmaceutical group AstraZeneca announced on Tuesday a pause in clinical trials of its experimental vaccine against Covid-19.
The onset of a “potentially unexplained illness”, possibly a serious side effect, in a participant.
Vaccine against Covid-19: 7 questions to understand everything
AstraZeneca is the industrial partner of the UK University of Oxford, and their vaccine is one of the most advanced Western projects, tested on tens of thousands of volunteers in the UK, Brazil, South Africa and since August 31, the United States, in what is called phase 3 of the trials, the last, to verify safety and efficacy.
Hundreds of millions of doses already pre-sold
"It is a routine action that is required as soon as a potentially unexplained disease appears in one of the trials, during the investigation, in order to maintain the integrity of the trials," continued the spokesperson for the company in this release.
The nature and severity of the event is unknown but, according to the Statnews website, the affected person should recover.
This is the first known suspension of a clinical trial concerning an experimental vaccine against Covid-19.
Vaccine against Covid-19: "Convincing the French will be a big headache"
Depending on the length of the investigations, this could have an impact on the tight development schedule.
The British Minister of Health had said on Monday that he hoped for results from AstraZeneca's trials by the end of the year or the beginning of 2021. The laboratory has already pre-sold hundreds of millions of doses to multiple countries, in case his vaccine proves its effectiveness.